当前位置： SCI文献检索 > Blood Cancer Journal期刊下所有文献 > Decision analysis for donor selection in stem cell transplantation-HLA-8/8 allele-matched unrelated donor vs HLA-1 AG mismatched related donor.

Decision analysis for donor selection in stem cell transplantation-HLA-8/8 allele-matched unrelated donor vs HLA-1 AG mismatched related donor.

Abstract：

:Risk of relapse during the unrelated donor coordination period biases comparisons between allogeneic hematopoietic stem cell transplantation from an HLA 8 of 8 allele-matched unrelated donor (8/8 MUD) and that from a related donor with an HLA-1 antigen mismatch in the graft-versus-host (GVH) direction (RD/1AGMM-GVH). To reduce this bias, we performed a decision analysis focusing on acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in first complete remission (CR1). The primary outcome measure was 5-year survival probability with or without quality-of-life (QOL) adjustment. A baseline analysis showed that the decision to perform MUD transplantation was superior to that to perform RD/1AGMM-GVH transplantation for patients with AML or ALL. However, in the ALL cohort, the direction of superiority was reversed when the interval between CR1 and 8/8 MUD transplantation was >5.5 months (without QOL adjustment) or >6 months (after QOL adjustment) or when overall survival of RD/1AGMM-GVH transplantation improved by 1.3% without QOL adjustment and 2.1% after QOL adjustment. In conclusion, 8/8 MUD should be prioritized in transplantation for AML and ALL in CR1. However, the MUD coordination period and improvements in RD/1AGMM-GVH transplantation might change the donor selection priority in transplantation for ALL in CR1.

journal_name

Blood Cancer J

journal_title

Blood cancer journal

authors

Kanda J,Fuji S,Kato S,Takami A,Tanaka J,Miyamura K,Ohashi K,Fukuda T,Ozawa Y,Kanamori H,Eto T,Kobayashi N,Iwato K,Morishima Y,Sakamaki H,Atsuta Y,Kanda Y,HLA Working Group.,Donor\/Source Working Group.,Adult AML Wor

doi

10.1038/bcj.2014.85

subject

Has Abstract

pub_date

2014-12-05 00:00:00

pages

e263

issn

2044-5385

pii

bcj201485

journal_volume

4

pub_type

临床试验,杂志文章,多中心研究

相关文献

Blood Cancer Journal文献大全
  • Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma.

    abstract：:Effect of alternative splicing (AS) on diffuse large B-cell lymphoma (DLBCL) pathogenesis and survival has not been systematically addressed. Here, we compared differentially expressed genes and exons in association with survival after chemoimmunotherapy, and between germinal center B-cell like (GCB) and activated B-c...

    journal_title：Blood cancer journal

    pub_type： 杂志文章,多中心研究

    doi：10.1038/bcj.2017.71

    authors： Leivonen SK,Taskinen M,Cervera A,Karjalainen-Lindsberg ML,Delabie J,Holte H,Lehtonen R,Hautaniemi S,Leppä S

    更新日期：2017-08-25 00:00:00

  • MEK inhibitors as a chemotherapeutic intervention in multiple myeloma.

    abstract：:The Ras/Raf/MEK/extracellular signal regulated kinase (ERK) (Ras/mitogen-activated protein kinases (MAPK)) signal transduction pathway is a crucial mediator of many fundamental biological processes, including cellular proliferation, survival, angiogenesis and migration. Aberrant signalling through the Ras/MAPK cascade...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2013.1

    authors： Chang-Yew Leow C,Gerondakis S,Spencer A

    更新日期：2013-03-22 00:00:00

  • Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients.

    abstract：:Autologous stem cell transplant (aHSCT) is associated with improved survival for multiple myeloma (MM) patients but may be associated with second primary malignancy (SPM) development. Using the California Cancer Registry linked to statewide hospitalization data, we determined the cumulative incidence (CMI) of SPMs mor...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/s41408-020-00400-4

    authors： Rosenberg AS,Brunson A,Tuscano J,Jonas BA,Hoeg R,Wun T,Keegan THM

    更新日期：2021-01-07 00:00:00

  • Dysregulated choline metabolism in T-cell lymphoma: role of choline kinase-α and therapeutic targeting.

    abstract：:Cancer cells have distinct metabolomic profile. Metabolic enzymes regulate key oncogenic signaling pathways and have an essential role on tumor progression. Here, serum metabolomic analysis was performed in 45 patients with T-cell lymphoma (TCL) and 50 healthy volunteers. The results showed that dysregulation of choli...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2015.10

    authors： Xiong J,Bian J,Wang L,Zhou JY,Wang Y,Zhao Y,Wu LL,Hu JJ,Li B,Chen SJ,Yan C,Zhao WL

    更新日期：2015-03-13 00:00:00

  • Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy.

    abstract：:The outcomes for patients with chronic myeloid leukemia have improved dramatically with the development and availability of BCR-ABL1 tyrosine kinase inhibitors (TKIs) over the past decade. TKI therapy has a superior safety profile compared with the previous standard of care, interferon-α, and most adverse events (AEs)...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2012.30

    authors： Deangelo DJ

    更新日期：2012-10-19 00:00:00

  • Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study.

    abstract：:We report the final analysis of the PROLONG study on ofatumumab maintenance in relapsed chronic lymphocytic leukemia (CLL). In all, 480 patients with CLL in complete or partial remission after second- or third-line treatment were randomized 1:1 to ofatumumab (300 mg first week, followed by 1000 mg every 8 weeks for up...

    journal_title：Blood cancer journal

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/s41408-019-0260-2

    authors： van Oers M,Smolej L,Petrini M,Offner F,Grosicki S,Levin MD,Davis J,Banerjee H,Stefanelli T,Hoever P,Geisler C

    更新日期：2019-12-04 00:00:00

  • Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia.

    abstract：:Acute myeloid leukemia (AML) frequently comprises mutations in genes that cause perturbation in intracellular signaling pathways, thereby altering normal responses to growth factors and cytokines. Such oncogenic cellular signal transduction may be therapeutic if targeted directly or through epigenetic regulation. We t...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2011.2

    authors： Skavland J,Jørgensen KM,Hadziavdic K,Hovland R,Jonassen I,Bruserud O,Gjertsen BT

    更新日期：2011-02-01 00:00:00

  • Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation.

    abstract：:T-cell large granular lymphocytic (T-LGL) leukemia is a clonal disease characterized by the expansion of mature CD3+CD8+ cytotoxic T cells. It is often associated with autoimmune disorders and immune-mediated cytopenias. Our recent findings suggest that up to 40% of T-LGL patients harbor mutations in the STAT3 gene, w...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2013.65

    authors： Andersson EI,Rajala HL,Eldfors S,Ellonen P,Olson T,Jerez A,Clemente MJ,Kallioniemi O,Porkka K,Heckman C,Loughran TP Jr,Maciejewski JP,Mustjoki S

    更新日期：2013-12-06 00:00:00

  • Improved outcome for AML patients over the years 2000-2014.

    abstract：:Few recent studies from registries have reported an improvement in overall survival of younger patients with acute myeloid leukemia (AML). However, reasons for this improvement are not defined. We analyzed the therapeutic course and outcome of 976 patients treated by intensive chemotherapy between 2000 and 2014. The n...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/s41408-017-0011-1

    authors： Bertoli S,Tavitian S,Huynh A,Borel C,Guenounou S,Luquet I,Delabesse E,Sarry A,Laurent G,Attal M,Huguet F,Bérard E,Récher C

    更新日期：2017-11-29 00:00:00

  • Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib.

    abstract：:Heat shock protein 90 (Hsp90) is a promising target for anti-tumor therapy. We previously reported the anti-tumor activity of a novel Hsp90 inhibitor, KW-2478, in multiple myeloma (MM) as a single agent. In this study, we examined the combinational effect of KW-2478 and bortezomib, a proteasome inhibitor, in vitro and...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2012.13

    authors： Ishii T,Seike T,Nakashima T,Juliger S,Maharaj L,Soga S,Akinaga S,Cavenagh J,Joel S,Shiotsu Y

    更新日期：2012-04-01 00:00:00

  • Pim2 is important for regulating DNA damage response in multiple myeloma cells.

    abstract：:Pan proviral integrations of Moloney virus (PIM) inhibition in multiple myeloma (MM) results in reduced cell viability in tested human-derived MM cell lines and reduces tumor burden in xenograft mouse models, making PIMs important therapeutic targets for the disease. PIM kinase inhibitors are currently being tested cl...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2016.73

    authors： Ramachandran J,Santo L,Siu KT,Panaroni C,Raje N

    更新日期：2016-08-26 00:00:00

  • Myelofibrosis Treatment Algorithm 2018.

    abstract：:Two novel prognostic systems for primary myelofibrosis (PMF) were recently unveiled: GIPSS (genetically inspired prognostic scoring system) and MIPSS70 (mutation-enhanced international prognostic scoring system for transplant-age patients). GIPSS is based exclusively on genetic markers: mutations and karyotype. MIPSS7...

    journal_title：Blood cancer journal

    pub_type： 杂志文章,评审

    doi：10.1038/s41408-018-0109-0

    authors： Tefferi A,Guglielmelli P,Pardanani A,Vannucchi AM

    更新日期：2018-07-31 00:00:00

  • Molecular pathways of early CD105-positive erythroid cells as compared with CD34-positive common precursor cells by flow cytometric cell-sorting and gene expression profiling.

    abstract：:Special attention has recently been drawn to the molecular network of different genes that are responsible for the development of erythroid cells. The aim of the present study was to establish in detail the immunophenotype of early erythroid cells and to compare the gene expression profile of freshly isolated early er...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2012.45

    authors： Machherndl-Spandl S,Suessner S,Danzer M,Proell J,Gabriel C,Lauf J,Sylie R,Klein HU,Béné MC,Weltermann A,Bettelheim P

    更新日期：2013-01-11 00:00:00

  • Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significance.

    abstract：:We previously reported that CagA can be translocated into B cells in Helicobacter pylori (HP) coculture media, and the translocation appears biologically significant as activation of the relevant cellular pathways was noticed. In this study, we further explore if CagA can be detected in malignant B cells of HP-positiv...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2013.22

    authors： Kuo SH,Chen LT,Lin CW,Wu MS,Hsu PN,Tsai HJ,Chu CY,Tzeng YS,Wang HP,Yeh KH,Cheng AL

    更新日期：2013-07-12 00:00:00

  • Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.

    abstract：:This corrects the article DOI: 10.1038/bcj.2015.86. ...

    journal_title：Blood cancer journal

    pub_type： 杂志文章,已发布勘误

    doi：10.1038/bcj.2017.100

    authors： Saito H,Maruyama D,Maeshima AM,Makita S,Kitahara H,Miyamoto K,Fukuhara S,Munakata W,Suzuki T,Kobayashi Y,Taniguchi H,Tobinai K

    更新日期：2017-11-03 00:00:00

  • A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.

    abstract：:Genomic lesions are not investigated during routine diagnostic workup for multiple myeloma (MM). Cytogenetic studies are performed to assess prognosis but with limited impact on therapeutic decisions. Recently, several recurrently mutated genes have been described, but their clinical value remains to be defined. There...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2016.72

    authors： Bolli N,Li Y,Sathiaseelan V,Raine K,Jones D,Ganly P,Cocito F,Bignell G,Chapman MA,Sperling AS,Anderson KC,Avet-Loiseau H,Minvielle S,Campbell PJ,Munshi NC

    更新日期：2016-09-02 00:00:00

  • Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.

    abstract：:FMS-like tyrosine kinase 3 (FLT3) is the most commonly mutated gene found in acute myeloid leukemia (AML) patients and its activating mutations have been proven to be a negative prognostic marker for clinical outcome. Pacritinib (SB1518) is a tyrosine kinase inhibitor (TKI) with equipotent activity against FLT3 (IC(50...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2011.43

    authors： Hart S,Goh KC,Novotny-Diermayr V,Tan YC,Madan B,Amalini C,Ong LC,Kheng B,Cheong A,Zhou J,Chng WJ,Wood JM

    更新日期：2011-11-01 00:00:00

  • MR-1 blocks the megakaryocytic differentiation and transition of CML from chronic phase to blast crisis through MEK dephosphorylation.

    abstract：:Chronic myelogenous leukemia (CML) evolves from a chronic phase characterized by the Philadelphia chromosome as the sole genetic abnormality and the accumulation of mature cells in peripheral blood into blast crisis, which is characterized by the rapid expansion of myeloid- or lymphoid-differentiation-arrested blast c...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2013.5

    authors： Zhao W,He H,Ren K,Li B,Zhang H,Lin Y,Shao RG

    更新日期：2013-03-29 00:00:00

  • Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia.

    abstract：:To diagnose juvenile myelomonocytic leukemia (JMML) is sometimes challenging, because around 10% of patients lack molecular abnormalities affecting Ras-MAPK (mitogen-activated protein kinase) pathway and other diseases such as cytomegalovirus infection can mimic clinical signs of JMML. In order to validate a phospho-s...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2013.56

    authors： Hasegawa D,Bugarin C,Giordan M,Bresolin S,Longoni D,Micalizzi C,Ramenghi U,Bertaina A,Basso G,Locatelli F,Biondi A,Te Kronnie G,Gaipa G

    更新日期：2013-11-15 00:00:00

  • Autophagy collaborates with ubiquitination to downregulate oncoprotein E2A/Pbx1 in B-cell acute lymphoblastic leukemia.

    abstract：:B-cell acute lymphoblastic leukemia (B-ALL) accounts for the most cancer incidences in children. We present here that autophagy is downregulated in pediatric B-ALL, suggesting a possible link between autophagy failure and pediatric B-ALL leukemogenesis. With a pediatric t(1;19) B-ALL xenograft mouse model, we show her...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2014.96

    authors： Yuan N,Song L,Lin W,Cao Y,Xu F,Liu S,Zhang A,Wang Z,Li X,Fang Y,Zhang H,Zhao W,Hu S,Wang J,Zhang S

    更新日期：2015-01-23 00:00:00

  • T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.

    abstract：:Preclinical and emerging clinical studies demonstrate that bispecific T-cell engaging (BiTE) antibody constructs can potently lyse targeted tumor cells, but the determinants for their activity remain incompletely understood. Using human acute myeloid leukemia (AML) cell lines engineered to overexpress individual T-cel...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2015.68

    authors： Laszlo GS,Gudgeon CJ,Harrington KH,Walter RB

    更新日期：2015-08-21 00:00:00

  • Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience.

    abstract：:Although the introduction of immunotherapy has improved outcomes for follicular lymphoma (FL) patients, histological transformation (HT) and early relapse still confer a poor prognosis. We sought to describe the patterns of change in treatment, response, and outcome of FL patients at our institution over the last four...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/s41408-020-0299-0

    authors： Mozas P,Nadeu F,Rivas-Delgado A,Rivero A,Garrote M,Balagué O,González-Farré B,Veloza L,Baumann T,Giné E,Delgado J,Villamor N,Campo E,Magnano L,López-Guillermo A

    更新日期：2020-03-05 00:00:00

  • CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.

    abstract：:Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a devastating event occurring in ~ 5% of patients treated with R-CHOP. We hypothesized that adding lenalidomide to R-CHOP (R2CHOP) may decrease the risk of CNS relapse. We analyzed records for patients with DLBCL from two R2CHOP trials. W...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/s41408-018-0097-0

    authors： Ayed AO,Chiappella A,Pederson L,Laplant BR,Congiu AG,Gaidano G,Spina M,Re A,Cavallo F,Musuraca G,Macon WR,Witzig T,Vitolo U,Nowakowski GS

    更新日期：2018-06-26 00:00:00

  • Loss of the xeroderma pigmentosum group B protein binding site impairs p210 BCR/ABL1 leukemogenic activity.

    abstract：:Previous studies have demonstrated that p210 BCR/ABL1 interacts directly with the xeroderma pigmentosum group B (XPB) protein, and that XPB is phosphorylated on tyrosine in cells that express p210 BCR/ABL1. In the current study, we have constructed a p210 BCR/ABL1 mutant that can no longer bind to XPB. The mutant has ...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2013.36

    authors： Pannucci NL,Li D,Sahay S,Thomas EK,Chen R,Tala I,Hu T,Ciccarelli BT,Megjugorac NJ,Adams Iii HC,Rodriguez PL,Fitzpatrick ER,Lagunoff D,Williams DA,Whitehead IP

    更新日期：2013-08-16 00:00:00

  • Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

    abstract：:Carfilzomib (Cfz) has been associated with an ~5% incidence of unexplained and unpredictable cardiovascular toxicity in clinical trials. We therefore implemented a detailed, prospective, clinical cardiac and renal evaluation of 62 Cfz-treated myeloma patients, including serial blood pressure (BP), creatinine, troponin...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2015.112

    authors： Rosenthal A,Luthi J,Belohlavek M,Kortüm KM,Mookadam F,Mayo A,Fonseca R,Bergsagel PL,Reeder CB,Mikhael JR,Stewart AK

    更新日期：2016-01-15 00:00:00

  • Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.

    abstract：:This phase 2 trial was designed to evaluate ixazomib, an orally bioavailable proteasome inhibitor, in patients with myeloma who have limited prior exposure to bortezomib. Thirty-three patients with relapsed multiple myeloma were enrolled. Ixazomib was given at 5.5 mg weekly for 3 of 4 weeks. Dexamethasone was added fo...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/bcj.2015.60

    authors： Kumar SK,LaPlant B,Roy V,Reeder CB,Lacy MQ,Gertz MA,Laumann K,Thompson MA,Witzig TE,Buadi FK,Rivera CE,Mikhael JR,Bergsagel PL,Kapoor P,Hwa L,Fonseca R,Stewart AK,Chanan-Khan A,Rajkumar SV,Dispenzieri A

    更新日期：2015-08-14 00:00:00

  • High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.

    abstract：:Mutations in exon 9 of the calreticulin gene (CALR) frequently occur in patients with chronic myeloproliferative neoplasms (MPN). Patients exhibit spontaneous cellular immune responses to epitopes derived from the mutant CALR C-terminus, and CALR-mutant-specific T cells recognize autologous CALR-mutant malignant cells...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/s41408-018-0166-4

    authors： Holmström MO,Ahmad SM,Klausen U,Bendtsen SK,Martinenaite E,Riley CH,Svane IM,Kjær L,Skov V,Ellervik C,Pallisgaard N,Hasselbalch HC,Andersen MH

    更新日期：2019-01-17 00:00:00

  • Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment.

    abstract：:Redirecting T cells to specifically kill malignant cells has been validated as an effective anti-cancer strategy in the clinic with the approval of blinatumomab for acute lymphoblastic leukemia. However, the immunosuppressive nature of the tumor microenvironment potentially poses a significant hurdle to T cell therapi...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/s41408-020-0331-4

    authors： Nair-Gupta P,Rudnick SI,Luistro L,Smith M,McDaid R,Li Y,Pillarisetti K,Joseph J,Heidrich B,Packman K,Attar R,Gaudet F

    更新日期：2020-06-01 00:00:00

  • Interpretation of cytogenetic results in multiple myeloma for clinical practice.

    abstract：:The interpretation of cytogenetic abnormalities in multiple myeloma (MM) is often a challenging task. MM is characterized by several cytogenetic abnormalities that occur at various time points in the disease course. The interpretation of cytogenetic results in MM is complicated by the number and complexity of the abno...

    journal_title：Blood cancer journal

    pub_type： 杂志文章,评审

    doi：10.1038/bcj.2015.92

    authors： Rajan AM,Rajkumar SV

    更新日期：2015-10-30 00:00:00

  • Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.

    abstract：:High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. We report an updated subgroup analysi...

    journal_title：Blood cancer journal

    pub_type： 杂志文章

    doi：10.1038/s41408-020-00375-2

    authors： Kaufman JL,Dimopoulos MA,White D,Benboubker L,Cook G,Leiba M,Morton J,Joy Ho P,Kim K,Takezako N,Moreau P,Sutherland HJ,Magen H,Iida S,Kim JS,Miles Prince H,Cochrane T,Oriol A,Bahlis NJ,Chari A,O'Rourke L,Trivedi

    更新日期：2020-11-03 00:00:00